This is for info only, not medical advice. Tesamorelin needs a prescription. CJC-1295 is not FDA-approved. Most U.S. sales are tagged "not for human use." Talk to a licensed doctor before any peptide choice.

Both are in the same family. Both are GHRH analogs. Both raise GH and IGF-1. From there, the two split on structure, evidence, legal status, and price. For the wider GHRH/secretagogue picture, see our growth hormone peptides overview covering sermorelin, ipamorelin, and CJC-1295.

A 2026 meta-analysis of five RCTs found tesamorelin cut belly fat by a mean of 27.71 cm² versus placebo (ScienceDirect, 2026). CJC-1295 has no such human data. That gap drives most of the points below.

What we looked at

Mechanism — peptide structure, receptor binding, half-life
Evidence — human RCTs, sample sizes, endpoints
Legal status — FDA approval, compounding rules
Cost in 2026 — brand, compounded, and gray-market pricing
Safety — known side effects, monitoring, long-term unknowns

Sources are FDA labels, peer-reviewed trials on PubMed, and Theratechnologies press releases. Vendor blogs and forum posts were left out.

At a glance: 10 differences

#	Dimension	Tesamorelin	CJC-1295	Winner
1	Peptide structure	Synthetic GHRH 1-44 (44 amino acids)	Modified GHRH 1-29 with 4 substitutions	Tied (different goals)
2	Half-life	~26 minutes	~30 min without DAC; 6-8 days with DAC	CJC-1295 with DAC
3	FDA status	Approved (Egrifta SV, Egrifta WR)	Not approved; was on 503A Category 2	Tesamorelin
4	RCT count in humans	5+ randomized controlled trials	2 short Phase I trials	Tesamorelin
5	Visceral fat evidence	-27.71 cm² mean reduction vs placebo	No dedicated body-composition RCT	Tesamorelin
6	Liver fat (NAFLD) evidence	-32% hepatic fat at 12 months	No published liver outcome data	Tesamorelin
7	Prescription path	Specialty pharmacy via HIV provider	Compounding pharmacy or research vendor	Tesamorelin (legal clarity)
8	2026 monthly cost	$2,400-$3,085 brand; $150-$300 compounded	$50-$300 gray market	Depends on legal preference
9	Insurance coverage	Yes, for HIV lipodystrophy	None	Tesamorelin
10	Known safety signal	IGF-1 elevation, glucose intolerance	One cardiac death in Phase II; injection-site reactions	Tesamorelin (better characterized)

1. Peptide structure — tesamorelin is full-length GHRH; CJC-1295 is a modified fragment

Tesamorelin is a synthetic copy of the full 44-amino-acid human GHRH. A trans-3-hexenoic acid group is added at the N-terminus to slow breakdown (FDA label, 2019).

CJC-1295 starts from the shorter GHRH 1-29 fragment. It swaps amino acids at positions 2, 8, 15, and 27 to resist enzyme breakdown (Biotech Peptides, 2026).

Both bind the GHRH receptor. The structure gap matters less than the half-life gap from the DAC add-on.

2. Half-life — CJC-1295 with DAC lasts days; tesamorelin clears in under an hour

Tesamorelin has a plasma half-life of about 26 minutes after a shot (Drugs.com monograph, 2024). It makes a single GH pulse and then clears.

CJC-1295 with DAC (drug affinity complex) binds to serum albumin. Its half-life jumps to 5.8-8.1 days (J Clin Endocrinol Metab, 2006). IGF-1 stays high 9-11 days from one dose.

Without DAC, "modified GRF 1-29" acts more like tesamorelin. Short pulses, ~30-minute half-life. Most gray-market CJC-1295 sold now is the DAC kind.

3. FDA status — only tesamorelin is approved for humans

Tesamorelin is FDA-approved as Egrifta SV (2010 first nod; 2019 reformulation) and Egrifta WR (2025 weekly version). Both are for HIV-linked lipodystrophy (Theratechnologies, 2025).

CJC-1295 has no FDA approval. The FDA placed it on the 503A "Category 2" list in 2023. That meant compounding pharmacies could not make it for routine use (ProPublica, 2025). In September 2024, the FDA pulled it from Category 2 and sent it for review. No final ruling yet.

CJC-1295 sold online as a "research chemical" is tagged "not for human use." Buying it to inject sits in a legal gray zone — see our where to buy peptides legally guide for the 10 sourcing channels ranked by legality.

4. RCT count — tesamorelin has 5+ trials; CJC-1295 has 2 short ones

A 2026 review found five RCTs of tesamorelin in HIV-linked lipodystrophy (ScienceDirect, 2026). Pooled enrollment topped 1,400 patients.

CJC-1295's human evidence base is two Phase I trials from 2006. Both had fewer than 50 healthy adults (J Clin Endocrinol Metab, 2006). Both looked at drug levels over 28-49 days. Neither measured belly fat or lean mass.

No Phase II or Phase III CJC-1295 trial exists in print. That's a big gap when comparing the two.

5. Visceral fat — only tesamorelin has direct RCT proof

The 2026 meta-analysis found tesamorelin cut visceral fat by a mean of 27.71 cm² (95% CI -38.37 to -17.06; p<0.001) versus placebo across five trials (ScienceDirect, 2026). Trunk fat fell too.

A post hoc analysis of the Phase III trial found tesamorelin cut belly fat whether or not "buffalo hump" was present (PMC, 2020).

CJC-1295 has no RCT that measured belly fat. Claims about its fat-loss effect rest on GH and IGF-1 levels, not direct fat measurement.

6. Liver fat — tesamorelin cut hepatic fat 32%; CJC-1295 has no liver data

Stanley and team at Mass General ran a 12-month trial of tesamorelin in HIV patients with NAFLD. Liver fat fell about 32% versus no change in placebo (Lancet HIV, 2019).

A follow-up showed tesamorelin slowed liver fibrosis in the same group (JCI Insight, 2020).

A Phase II trial of tesamorelin in non-HIV NAFLD is underway (ClinicalTrials.gov NCT03375788). CJC-1295 has no liver data in print.

7. Prescription path — tesamorelin has one; CJC-1295 does not

Tesamorelin is filled through specialty pharmacies on a script from an HIV doctor or endocrinologist. The approved use is HIV-linked lipodystrophy. Off-label use for general body comp is legal but not paid by insurance.

CJC-1295 has no real prescription path in the U.S. Some compounding pharmacies sold it before the 2023 Category 2 tag. After September 2024, the legal status is in flux while the FDA review plays out (ProPublica, 2025).

Most U.S. buyers get CJC-1295 from research-chemical sites. These tag products "not for human consumption." That tag does not protect the buyer.

8. Cost in 2026 — brand tesamorelin is 10-30x the cost of gray-market CJC-1295

Brand Egrifta SV runs $2,400-$2,800 per month without insurance. Egrifta WR (the weekly version) lists at $3,085 per month (Better Results Book, 2026).

Compounded tesamorelin from telehealth firms runs $150-$300 per month (PrymaLab, 2026). These are off-label and not paid by insurance.

Gray-market CJC-1295 (often stacked with ipamorelin) runs $50-$300 per month from research vendors. The low price reflects no pharmacy oversight, no sterility tests, and no identity checks. Buyers comparing research-channel vendors should review our best peptide vendors ranked by third-party testing first.

What buyers report (from r/Peptides and r/PeptideForum, 2023–2025):

"Tesamorelin is a pretty expensive peptide. You're probably looking at about $210 to run a typical 3-month cycle, plus the necessary bloodwork to monitor effects. That's at Chinese prices. To run the same cycle at the prices offered by some US-based single vial resellers you'd be looking at $1800." — u/SubParMarioBro on r/Retatrutide, 2025-04

"tesamorelin can get expensive. like crazy expensive. it goes by the name engrifta. it;s like $8,000 for a 30 day supply. Funny thing is its a peptide and also crazy cheap on the grey market. I think the best prices ive found are about $50 for a 10mg vial which would last about a week or two depending on dose" — u/Big_Balance_1544 on r/PeptideForum, 2025-03

"I've got NAD+ from Reset Wellness and they offer 'Tesamorelin/Ipamorelin'. I could stomach these prices too see if it works. $350/1-month injection $675/2-month injection" — u/Noellia1st on r/PeptideForum, 2025-04

"From Transcend who MindPump uses — 'Quantity: 8x 12mg Tesamorelin + 6mg Ipamorelin vials. Cost: $3974 for 4 months of medication (buy-3-get-1 price)'" — u/Schyluer on r/Peptides, 2023-07

Treat these as anecdotes, not buying advice. Prices listed here span legitimate U.S. telehealth, brand-name pharmacy, and gray-market sources — the legal status of each path varies and is covered in Where to Buy Peptides Legally in 2026.

9. Insurance coverage — only brand tesamorelin gets paid

Insurance covers brand Egrifta SV and Egrifta WR for HIV-linked lipodystrophy when prior-auth is met (Molina Healthcare PA criteria, 2024). Theratechnologies runs a patient-assistance program that can cut co-pays to $0-$50 for qualified patients.

Compounded tesamorelin for off-label body comp is not covered. CJC-1295 is never covered. Patients pay cash for both.

For broader context on what's documented across the peptide therapy category, see our peptide therapy side effects and risks guide.

10. Safety — tesamorelin's risks are mapped; CJC-1295's are not

In tesamorelin's main trials, 7.6% of treated patients had injection-site itch versus 0.8% on placebo. About 47% had IGF-1 levels above 2 SDS at 26 weeks (FDA label, 2019). About 5% had a rise in HbA1c (≥6.5%) versus 1% on placebo. The label calls for baseline and periodic glucose checks.

CJC-1295's safety profile rests on small Phase I data. A Phase II trial in 192 HIV patients had one cardiac death (ProPublica, 2025). Cause was not pinned down. The trial did not finish and full results were not published.

The FDA has flagged purity and immune-reaction risks for CJC-1295. Long-term human safety data does not exist.

Bottom line

For body comp with real human data, tesamorelin wins on every point that needs a trial. Five RCTs. FDA approval. A mapped safety profile. Insurance coverage for the approved use.

CJC-1295 is cheaper and lasts longer in the body. Neither offsets the lack of human data, the legal gray zone, or the unknown long-term risk. Anyone weighing either choice should work with a licensed doctor. Source the drug from a pharmacy that can verify identity, purity, and potency.

Frequently asked questions

Is CJC-1295 legal in the U.S. in 2026? CJC-1295 is not FDA-approved for human use. It was placed on the FDA's 503A Category 2 list in 2023 and sent for review in September 2024. As of May 2026, no final ruling has been issued (ProPublica, 2025). Most U.S. CJC-1295 sales are tagged "not for human use."

Why is tesamorelin so much pricier than CJC-1295? Brand Egrifta WR carries the costs of FDA approval, pharmacy supply, and safety tracking. Compounded tesamorelin drops to $150-$300/month. Gray-market CJC-1295 has none of these costs and none of the quality checks (PrymaLab, 2026).

Can tesamorelin be used for body comp outside HIV? Off-label use is legal but rare. Insurance only pays for the HIV lipodystrophy use. A Phase II trial in non-HIV NAFLD is ongoing (ClinicalTrials.gov NCT03375788). Until that trial reports, off-label use rests on HIV data.

Does CJC-1295 raise IGF-1 more than tesamorelin? A single dose of CJC-1295 with DAC raises IGF-1 by 1.5-3x for 9-11 days (J Clin Endocrinol Metab, 2006). Tesamorelin's IGF-1 spike is more pulse-like. About 47% of patients exceed +2 SDS at 26 weeks (FDA label, 2019). Long-term IGF-1 risk is unknown for both.

Should I take CJC-1295 with or without DAC? This is a clinical choice that needs a doctor. The DAC version has a 6-8 day half-life and easy dosing but stays high for days. The non-DAC version mimics natural GH pulses but needs many weekly shots. Neither is FDA-approved.

Researched and drafted by Theo Park, an AI editorial persona at AI Companion Pick, against published sources. Reviewed by our editorial team.

Tesamorelin vs CJC-1295: FDA Status, RCTs, Cost 2026

Quick Answer